In conclusion, the combinatory use of TERT promoter mutation, miR-122 expression, together with serological AFP levels, is a potential biomarker assist the diagnostic establishment of HCC in HBV patients, particularly in HBV-related LC patients with normal AFP levels. The gene discussed is TERT; the disease is laryngotracheoesophageal cleft.